Vitamin D and topical therapy.

Abstract

A sequential therapy regimen involving an initial clearing phase of daily applications of calcipotriene 0.005% ointment and halobetasol 0.05% ointment for 2 weeks, followed by halobetasol applied twice daily on weekends and calcipotriene applied twice daily on weekdays, has been shown to be effective in the management of chronic plaque psoriasis. As a clearing regimen, the combined use of halobetasol and calcipotriene for 2 weeks was superior to monotherapy with either agent. Subsequently, the use of halobetasol on weekends and calcipotriene on weekdays allowed 76% of patients to stay in remission for up to 6 months, compared with 40% of patients who applied halobetasol on weekends only and placebo on weekdays. Calcipotriene can be inactivated when mixed with some topical preparations; however, halobetasol propionate 0.05% ointment and cream have been shown to be compatible with calcipotriene for up to 2 weeks. The compatibility of calcipotriene and halobetasol permits the use of these agents together.

• Authors: Mark Lebwohl
• Journal: Cutis (Cutis) Vol. 70 Issue 5 Suppl Pg. 5-8 (Nov 2002) ISSN: 0011-4162 [Print] United States
• PMID: 12467332 (Publication Type: Journal Article, Review)

Chemical References

• Dermatologic Agents
• Ointments
• Vasoconstrictor Agents
• calcipotriene
• halobetasol
• Clobetasol
• Calcitriol

Topics

• Administration, Topical
• Calcitriol (administration & dosage, analogs & derivatives, therapeutic use)
• Clinical Trials as Topic
• Clobetasol (administration & dosage, analogs & derivatives, therapeutic use)
• Dermatologic Agents (administration & dosage, therapeutic use)
• Drug Administration Schedule
• Drug Therapy, Combination
• Humans
• Ointments
• Psoriasis (drug therapy)
• Treatment Outcome
• Vasoconstrictor Agents (administration & dosage, therapeutic use)